CliffBio
biologic

Sevenfact

coagulation factor VIIa (recombinant)-jncw

Loss of exclusivityApril 2032projected — 12-year biologic exclusivity estimate
CompanyLaboratoire Francais du Fractionnement et des Biotechnologies S.A.

Drug detail

Brand nameSevenfact
Active ingredientcoagulation factor VIIa (recombinant)-jncw
Strength1MG
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2020
Marketing statusRx

More from Laboratoire Francais du Fractionnement et des Biotechnologies S.A.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Sevenfact patent cliff — loss of exclusivity April 2032 | CliffBio